Cobolimab

Cobolimab Suppliers list
Company Name: BOC Sciences
Tel: 16314854226; +16314854226
Email: inquiry@bocsci.com
Products Intro: Product Name:Cobolimab
CAS:2022215-65-0
Purity:95% Remarks:Please reach out to us for more information about custom solutions.
Company Name: Shanghai YuanYe Biotechnology Co., Ltd.  
Tel: 021-61312847; 18021002903
Email: 3008007409@qq.com
Products Intro: Product Name:Cobolimab (anti-TIM-3)
CAS:2022215-65-0
Purity:ExactAb?, Validated, Carrier Free, Low Endotoxin, Azide Free Package:100μg Remarks:K14110
Company Name: ShangHai Biochempartner Co.,Ltd  
Tel: 177-54423994 17754423994
Email: 2853530910@QQ.com
Products Intro: Product Name:Cobolimab
CAS:2022215-65-0
Purity:95% Package:100ug;500ug;1mg
Company Name: Guangzhou Hongyuan Chemical Co.,Ltd  
Tel: 15817493340
Email: 981810490@qq.com
Products Intro: Product Name:Cobolimab
CAS:2022215-65-0
Purity:95% Package:1mg;1g;100g
Company Name: Wuhan Chemstan Biotechnology Co., Ltd.  
Tel: 027-65317797 15926423062
Email: 422450190@qq.com
Products Intro: Product Name:Cobolimab
Purity:>95%;1mg/ml Package:200ug;500ug;1mg
Cobolimab Basic information
Product Name:Cobolimab
Synonyms:Cobolimab;Research Grade Cobolimab(DHJ28401);TSR-022|||GSK4069889;Research Grade Cobolimab;Cobolimab (anti-TIM-3)
CAS:2022215-65-0
MF:
MW:0
EINECS:
Product Categories:
Mol File:Mol File
Cobolimab Structure
Cobolimab Chemical Properties
form Liquid
color Colorless to light yellow
Safety Information
MSDS Information
Cobolimab Usage And Synthesis
UsesCobolimab (TSR-022) is an anti-TIM-3 monoclonal antibody. Cobolimab mediates the internalization of TIM3 with an IC50 value of 0.4464 nM. Cobolimab has potential application in solid tumors and non-small cell lung cancer (NSCLC)[1][2][3].
References[1] Falchook G S, et al. Phase 1 trial of TIM-3 inhibitor cobolimab monotherapy and in combination with PD-1 inhibitors nivolumab or dostarlimab (AMBER)[J]. 2022.
[2] Markham A. Dostarlimab: First Approval. Drugs. 2021 Jul;81(10):1213-1219. DOI:10.1007/s40265-021-01539-5
[3] Kuang Z, et al. A novel antibody targeting TIM-3 resulting in receptor internalization for cancer immunotherapy. Antib Ther. 2020 Nov 9;3(4):227-236. DOI:10.1093/abt/tbaa022
[4] Sun CY, et al. T cell exhaustion drives osteosarcoma pathogenesis. Ann Transl Med. 2021 Sep;9(18):1447. DOI:10.21037/atm-21-3928
Cobolimab Preparation Products And Raw materials
Tag:Cobolimab(2022215-65-0) Related Product Information
Tinurilimab Vedolizumab Ibalizumab Meplazumab Enfortumab Vedotin Lirilumab bimekizumab Tamrintamab Fresolimumab Tigatuzumab